• Allarity Therapeutics reported recently awarded patents tied to its Drug Response Predictor strategy for stenoparib, aiming to strengthen commercial exclusivity.
• The company said the patents support use of its stenoparib-DRP test as a companion diagnostic while keeping control of the clinical test.
• Management framed the patent progress as a key step toward a DRP-guided pivotal trial for stenoparib and an eventual FDA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300900PRIMZONEFULLFEED1001275387) on September 30, 2026, and is solely responsible for the information contained therein.